QQ客服 官方微博 反馈留言

浏览/检索结果: 共6条，第1-6条 帮助 限定条件 发表日期：2019     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Targeting oxidative pentose phosphate pathway prevents recurrence in mutant Kras colorectal carcinomas 期刊论文 PLOS BIOLOGY, 2019, 卷号: 17, 期号: 8 作者:  Gao, WenChao;  Xu, YuTing;  Chen, Tao;  Du, ZunGuo;  Liu, XiuJuan 收藏  |  浏览/下载：19/0  |  提交时间：2019/12/05 SnO2 nanorods arrays functionalized TiO2 nanoparticles based UV photodetector with high and fast response 期刊论文 JOURNAL OF MATERIALS SCIENCE-MATERIALS IN ELECTRONICS, 2019, 卷号: 30, 页码: 13099-13107 作者:  Dong, Yanan;  Zheng, Wenji;  Yan, Xiaoming;  Dai, Yan;  Zhang, Xiujuan 收藏  |  浏览/下载：16/0  |  提交时间：2019/12/02 Effect of acupuncture at Neiguan point combined with amiodarone therapy on early recurrence after pulmonary vein electrical isolation in patients with persistent atrial fibrillation 期刊论文 JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2019, 卷号: 30, 期号: 6 作者:  Yin, Junkui;  Yang, Mei;  Yu, Shengbo;  Fu, Haixia;  Huang, He 收藏  |  浏览/下载：57/0  |  提交时间：2019/12/05 ablation  acupuncture  atrial fibrillation  early recurrences  Neiguan point   Trion-Induced Distinct Transient Behavior and Stokes Shift in WS Monolayers. 期刊论文 The journal of physical chemistry letters, 2019, 页码: 3763-3772 作者:  Peng Fan;  Biyuan Zheng;  Xingxia Sun;  Weihao Zheng;  Zheyuan Xu 收藏  |  浏览/下载：44/0  |  提交时间：2019/12/13 Trion-Induced Distinct Transient Behavior and Stokes Shift in WS Monolayers 期刊论文 The Journal of Physical Chemistry Letters, 2019, 卷号: Vol.10 No.13, 页码: 3763-3772 作者:  Peng Fan;  Biyuan Zheng;  Xingxia Sun;  Weihao Zheng;  Zheyuan Xu 收藏  |  浏览/下载：17/0  |  提交时间：2019/12/13 Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study 期刊论文 2019, 卷号: 257, 期号: 3, 页码: 529-541 作者:  Li, Xiaoxin;  Dai, Hong;  Li, Xiaorong;  Han, Mei;  Li, Jun 收藏  |  浏览/下载：170/0  |  提交时间：2020/01/03 Anti-vascular endothelial growth factor  Diabetic macular edema  Pro re nata  Ranibizumab